uniQure NV 2025年季度报告

FORM10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from _______ to _______Commission file number:001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) TheNetherlands(State or other jurisdiction of incorporation ororganization)Not applicable(I.R.S. Employer Identification No.) Paasheuvelweg 25a1105 BPAmsterdam, TheNetherlands(Address of principal executive offices) (Zip Code) +31-20-240-6000(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed bySection 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or forsuch shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes⌧No◻. Indicate by check mark whether the registrant has submitted electronically every InteractiveData File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of thischapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes⌧No◻. Indicate by check mark whether the registrant is a large accelerated filer, an acceleratedfiler, a non-accelerated filer, smaller reporting company or an emerging growth company. See thedefinitions of “large accelerated filer” “accelerated filer” and “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer⌧Smaller reporting company☐Emerging growth company☐ Large accelerated filer◻Non-accelerated filer◻ If an emerging growth company, indicate by check mark if the registrant has elected not touse the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 13 (a) of the Exchange Act◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2of the Exchange Act.)Yes☐No⌧ As of May 6, 2025, the registrant had54,748,496 ordinary shares, par value €0.05,outstanding. TABLE OF CONTENTS PagePART I – FINANCIAL INFORMATION Item 1Financial Statements2Item 2Management’s Discussion and Analysis of Financial Condition and Results ofOperations18Item 3Quantitative and Qualitative Disclosures About Market Risk30Item 4Controls and Procedures30PART II – OTHER INFORMATIONItem 1Legal Proceedings30Item1ARisk Factors31Item 2Unregistered Sales of Equity Securities, Use of Proceeds, and IssuerPurchases of Equity Securities76Item 3Defaults Upon Senior Securities76Item 4Mine Safety Disclosures76Item 5Other Information76Item 6Exhibits76 SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q contains “forward-looking statements” as definedunder federal securities laws. Forward-looking statements are based on our current expectations offuture events and many of these statements can be identified using terminology such as “believes,”“expects,” “anticipates,” “plans,” “may,” “will,” “projects,” “continues,” “estimates,” “potential,”“opportunity” and similar expressions. These forward-looking statements, include, but are notlimited to, statements concerning: our ability to fund our future operations; our financial position,revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing orthe time period for which our existing cash resources will be sufficient to meet our operatingrequirements; the success, progress, number, scope, cost, duration, timing or results of our researchand development activities, preclinical and clinical trials, including the timing for initiation orcompletion of or availability of results from any preclinical studies and clinical trials or for thesubmission, review or approval of any regulatory filing; the timing of, and our ability to, obtain andmaintain regulatory approvals for any of our product candidates; the potential benefits that may bederived from any of our product candidates; our strategies, prospects, plans, goals, expectations,forecasts or objectives; the success of our collaborations with third parties; our ability to identify anddevelopnew product candidates and technologies;our intellectual property position;ourcommercialization, marketing and manufacturing capabilities and strategy; our ability to identify,recruit and retain key personnel; our financial performance; developments and projections relating toour competitors in the industry; and our liquidity and working capital requirements. Forward-looking statements are only predictions based on management’s current views andassumptions and involve risks and uncertainties, and actual results could differ material